Oligonucleotide therapies offer new hope for treating central nervous system (CNS) disorders, including rare genetic and neurodegenerative diseases. Despite recent advances in molecular design and delivery systems, effective and reliable CNS delivery remains a major technical challenge, limiting clinical translation.
Intrathecal lumbar (IT-L) administration is emerging as a leading strategy to bypass the blood-brain barrier and achieve direct CNS exposure. However, success depends on precise dosing, rigorous verification, and robust pharmacokinetic (PK) data.
This article summarizes four essential best practices for improving CNS-targeted oligonucleotide delivery and validation, helping developers overcome key obstacles and accelerate early-stage development.
1. Establish Robust CNS Exposure Verification Methods
IT-L administration of oligos is popular because it can bypass the blood-brain barrier, delivering the drug directly into the cerebrospinal fluid (CSF). This enables rapid and effective action on the CNS, but the procedure can be technically demanding. The injection space is small, leaving little room for error and increasing the risk of either missed or partial dosing. With this method, verifying the extent of drug delivery to the target site is crucial.
A practical and commonly used method of verification is to analyze CSF drug concentrations post-dosing. This can be done by establishing a practical benchmark using the total CSF volume and dose to estimate the theoretical maximum concentration (TMC). Because CSF distribution is not homogeneous and is influenced by flow dynamics, this benchmark should be interpreted as a procedural verification metric rather than a predictor of tissue exposure. After estimating the maximum concentration achievable under the assumption of uniform distribution, successful delivery in validated preclinical models have been defined as achieving at least 25% of the TMC within the first hour post-dose. Researchers use these evaluation criteria to assess delivery techniques and identify potential issues early in the drug development process.
2. Utilize the Dual Catheter Port Approach to Improve Reliability
The dual catheter-port technique improves the consistency of IT-L dosing and enhances administration accuracy and sampling efficiency. The approach involves using catheter-ports for lumbar and intervertebral space drug delivery and CSF collection via the cisterna magna. Subcutaneous ports facilitate repeated dosing and sampling in conscious test articles.
In our studies, administration success rates have approached 100% when evaluated using the predefined 25% TMC benchmark. Compared with traditional IT puncture administration, the dual-catheter model offers a more reliable method for evaluating CNS-targeted therapies in preclinical research.
3. Don’t Underestimate the Importance of Tissue Sampling
While measuring drug concentration in CSF is crucial, it does not always reflect the drug’s distribution throughout the CNS. Oligos often exhibit high concentrations in the lumbar spinal cord near the injection site, according to studies, with lower concentrations observed in the cervical spinal cord closer to the brain.
Researchers should ensure they examine tissue samples from different segments of the spinal cord, brain, liver, and kidneys to more thoroughly understand this distribution. Time-concentration profiles can map drug distribution and movement patterns, guiding adjustments in dosing strategies. By taking this approach, researchers have a better understanding of therapeutic exposure and can aim to improve the efficacy of CNS-targeted treatments.
4. Select Appropriate In Vivo Models for Translational Relevance
Researchers should select in vivo models that closely resemble humans in both physiology and pharmacokinetics to ensure data are more relevant and translatable. This is essential for improving the overall validity of research findings.
While reusing non-naïve test subjects that have been previously dosed can help reduce study costs, it is important to consider the potential for immune responses (such as anti-drug antibody formation) or altered pharmacokinetics that may confound results. For pharmacokinetic (PK) studies, especially during the early discovery phase, using naive test subjects that have not previously received oligonucleotide treatments is recommended to avoid these confounding effects. Moreover, the use of naive animals is generally required for IND-enabling studies to meet regulatory expectations and ensure the integrity of the data.
A Final Word
New oligo therapies targeting CNS disorders can offer exciting and frustrating challenges in equal measure. Direct delivery into the subarachnoid space is currently one of the most effective ways to bypass the blood-brain barrier, but it requires precise and reliable dosing and accurate drug-level tracking.
New advances, such as dual-catheter-port methods and standardized success criteria, have enabled researchers to achieve more consistent and reliable results. Meanwhile, well-established PK profiles can be achieved through early testing of plasma and CSF concentrations, along with well-chosen test subjects.
As therapies progress beyond the nonclinical stage, enhanced delivery methods and evaluation strategies will be crucial to support accurate data, enabling more informed decisions throughout the development process. As CNS-targeted oligonucleotide therapies continue to evolve, collaboration is key to overcoming technical hurdles and achieving successful outcomes. We invite you to connect with our team to explore how, together, we can advance your CNS programs and bring new therapies to patients in need.
